BGNE Beigene Ltd ADR Stock Price

Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. One share of BGNE stock can currently be purchased for approximately $238.45.

BeiGene has a short interest ratio (“days to cover”) of 8.9. BeiGene Ltd. said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis o… Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment. The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction. Intellia Therapeutics reports loss for fourth-quarter 2022, in line with estimates. Prelude Therapeutics and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.

Monitor the latest movements within the BeiGene Ltd real time stock price chart below. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BGNE quote. Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

Research & Ratings BeiGene Ltd. ADR(BGNE)

One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $292.86. Morgan Stanley cut their target price on shares of BeiGene from $325.00 to $321.00 and set an “overweight” rating for the company in a research report on Tuesday, February 28th. Cowen upped their price objective on BeiGene from $213.00 to $262.00 and gave the company an “outperform” rating in a research report on Tuesday, February 28th. Guggenheim reissued a “buy” rating and issued a $350.00 target price on shares of BeiGene in a research note on Tuesday, February 28th.

• Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
• Advisors Asset Management Inc. now owns 1,244 shares of the company’s stock valued at $235,000 after acquiring an additional 262 shares during the last quarter.
• Now owns 885 shares of the company’s stock valued at $119,000 after buying an additional 68 shares in the last quarter.
• 9After taking multiple blows during the past year, Chinese mega cap stocks are beginning to show signs of life again.
• Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

They set a “buy” https://1investing.in/ and a $308.00 price objective on the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $292.86. BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide.

Why Alibaba and Other Chinese Stocks Could Face More Delisting Threats

This how much does netflix cost and what are the subscription options is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark. One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 05, 2023, there were 0 analysts who downgraded Beigene Ltd ’s stock and 1 analyst who upgraded over the last month. Rose 14.3% by late Thursday afternoon and closed the day 12.48% higher.

Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.

BeiGene Stock vs. The Competition

The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. Its geographical segments are China, the United States, and the Rest of the world. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 .

This news sentiment score is similar to the average news sentiment of Medical companies. According to analysts’ consensus price target of $292.86, BeiGene has a forecasted upside of 22.8% from its current price of $238.45. CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING—-BeiGene, a global biotechnology company, is convening diverse stakeholders to amplify the mental health needs of the cancer communit… A valuation method that multiplies the price of a company’s stock by the total number of outstanding shares. According to analysts, BeiGene’s stock has a predicted upside of 29.30% based on their 12-month price targets. Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report.

We recommend investors evaluate other financial metrics to understand its overall valuation. Before we jump into Beigene Ltd ’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. The price-earnings ratio is a company’s share price to the company’s Earnings per Share. The ratio is used for evaluating companies and to find out whether they are overvalued or undervalued. Fusion Mediawould like to remind you that the data contained in this website is not necessarily real-time nor accurate.

During the month of April, Beigene Ltd ’s stock price has reached a high of $242.44 and a low of $210.32. The other risk for BeiGene is whether the stock might be delisted if U.S. regulators find the company hasn’t been forthcoming in its accounting practices, a common concern among Chinese companies. In the long term, however, the stock has potential, with more than 60 clinical programs in its pipeline.

Markets

Based on an average daily trading volume, of 244,200 shares, the days-to-cover ratio is currently 8.9 days. Investing.com – BeiGene reported on Thursday second quarter erl ||earnings that missed analysts’ forecasts and revenue that fell short of expectations. Investing.com – BeiGene ADS reported on Wednesday first quarter erl ||earnings that beat analysts’ forecasts and revenue that fell short of expectations. At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision.

Provides a general description of the business conducted by this company. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. Click the link below and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2023 and why they should be in your portfolio. You can find your newly purchased BeiGene stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, and alternative assets.

For example, a price above its moving average is generally considered an upward trend or a buy. The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green. A number of other hedge funds have also recently added to or reduced their stakes in BGNE.

A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. There may be delays, omissions, or inaccuracies in the Information. The technique has proven to be very useful for finding positive surprises.